- Home
- CELC
CELC
Celcuity Inc.
as 02-21-2025 4:00pm EST
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 440.7M | IPO Year: | 2017 |
| Target Price: | $30.17 | AVG Volume (30 days): | 175.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.35 - $22.19 | Next Earning Date: | 03-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Celcuity Inc. News
CELC Breaking Stock News: Dive into CELC Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
GuruFocus.com
3 months ago
Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges
GlobeNewswire
3 months ago
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
GlobeNewswire
3 months ago
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
GuruFocus.com
4 months ago
Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
GuruFocus.com
4 months ago
Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings
Zacks
5 months ago
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
Compare CELC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELC Celcuity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.